Diligence memo · auto-generated · as of July 3, 2026
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Tvardi Therapeutics, Inc. operates in Pharmaceuticals, based in HOUSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tvardi Therapeutics, Inc. has raised $78M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $72M on 2021-06-03.
Most recent recorded round closed around 2021-06-03.
Valuation (modeled)modeled
Provath models Tvardi Therapeutics, Inc. at approximately $1.8B (range $235M–$4.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.12× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (112% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 5.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 23.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.